J. Norfleet

982 total citations
11 papers, 752 citations indexed

About

J. Norfleet is a scholar working on Genetics, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, J. Norfleet has authored 11 papers receiving a total of 752 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Genetics, 6 papers in Oncology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in J. Norfleet's work include Glioma Diagnosis and Treatment (8 papers), Cancer Treatment and Pharmacology (4 papers) and Brain Metastases and Treatment (4 papers). J. Norfleet is often cited by papers focused on Glioma Diagnosis and Treatment (8 papers), Cancer Treatment and Pharmacology (4 papers) and Brain Metastases and Treatment (4 papers). J. Norfleet collaborates with scholars based in United States and Thailand. J. Norfleet's co-authors include Annick Desjardins, James J. Vredenburgh, David A. Reardon, Henry S. Friedman, James E. Herndon, Roger E. McLendon, Sridharan Gururangan, Jennifer Marcello, John H. Sampson and Allan H. Friedman and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Neuro-Oncology.

In The Last Decade

J. Norfleet

10 papers receiving 732 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Norfleet United States 7 496 217 212 210 186 11 752
Markus W. Groß Germany 15 290 0.6× 295 1.4× 173 0.8× 171 0.8× 156 0.8× 24 866
Manfred Westphal Germany 7 239 0.5× 152 0.7× 303 1.4× 176 0.8× 204 1.1× 11 752
Marina Faedi Italy 13 412 0.8× 117 0.5× 157 0.7× 164 0.8× 96 0.5× 27 710
Michael Prados United States 15 522 1.1× 141 0.6× 226 1.1× 105 0.5× 228 1.2× 39 794
Ivan Lolli Italy 13 388 0.8× 80 0.4× 158 0.7× 202 1.0× 91 0.5× 40 672
Maxwell W. Tom United States 10 407 0.8× 118 0.5× 493 2.3× 177 0.8× 132 0.7× 10 975
Jung‐Il Lee South Korea 11 286 0.6× 179 0.8× 92 0.4× 71 0.3× 114 0.6× 14 515
Richard J. Dahl United States 12 217 0.4× 88 0.4× 280 1.3× 155 0.7× 122 0.7× 16 762
Heyoung L. McBride United States 11 151 0.3× 340 1.6× 196 0.9× 92 0.4× 222 1.2× 18 731
P.K. Sneed United States 11 331 0.7× 178 0.8× 103 0.5× 56 0.3× 223 1.2× 32 702

Countries citing papers authored by J. Norfleet

Since Specialization
Citations

This map shows the geographic impact of J. Norfleet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Norfleet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Norfleet more than expected).

Fields of papers citing papers by J. Norfleet

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Norfleet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Norfleet. The network helps show where J. Norfleet may publish in the future.

Co-authorship network of co-authors of J. Norfleet

This figure shows the co-authorship network connecting the top 25 collaborators of J. Norfleet. A scholar is included among the top collaborators of J. Norfleet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Norfleet. J. Norfleet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
2.
Lou, Emil, Ashley Sumrall, Scott Turner, et al.. (2012). Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. Journal of Neuro-Oncology. 109(1). 63–70. 144 indexed citations
3.
Reardon, David A., Andrew D. Norden, Annick Desjardins, et al.. (2011). Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. Journal of Neuro-Oncology. 106(2). 409–415. 63 indexed citations
4.
Bota, Daniela A., Zeynep Eroglu, David A. Reardon, et al.. (2011). Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma.. Journal of Clinical Oncology. 29(15_suppl). 2056–2056. 8 indexed citations
5.
Vredenburgh, James J., Sridharan Gururangan, David A. Reardon, et al.. (2010). Phase I trial of vandetanib and oral etoposide (VP-16) for recurrent malignant gliomas (MG).. Journal of Clinical Oncology. 28(15_suppl). 2038–2038.
6.
Sathornsumetee, Sith, Annick Desjardins, James J. Vredenburgh, et al.. (2010). Phase II trial of bevacizumab plus erlotinib for patients with recurrent malignant gliomas: Final results.. Journal of Clinical Oncology. 28(15_suppl). 2055–2055. 3 indexed citations
7.
Sathornsumetee, Sith, Annick Desjardins, James J. Vredenburgh, et al.. (2010). Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro-Oncology. 12(12). 1300–1310. 182 indexed citations
8.
Reardon, David A., Annick Desjardins, James J. Vredenburgh, et al.. (2009). Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. Journal of Neuro-Oncology. 96(2). 219–230. 181 indexed citations
9.
Reardon, David A., Annick Desjardins, James J. Vredenburgh, et al.. (2009). Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. British Journal of Cancer. 101(12). 1986–1994. 161 indexed citations
10.
Vredenburgh, James J., David A. Reardon, Annick Desjardins, et al.. (2009). Phase I trial of vendetanib and oral etoposide for recurrent malignant gliomas. Journal of Clinical Oncology. 27(15_suppl). e13016–e13016. 2 indexed citations
11.
Reardon, David A., Annick Desjardins, James J. Vredenburgh, et al.. (2009). Bevacizumab plus etoposide among recurrent malignant glioma patients: Phase II study final results. Journal of Clinical Oncology. 27(15_suppl). 2046–2046. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Markus W. Groß Breakdown of academic impact, for papers by Manfred Westphal Breakdown of academic impact, for papers by Marina Faedi Breakdown of academic impact, for papers by Michael Prados Breakdown of academic impact, for papers by Ivan Lolli Breakdown of academic impact, for papers by Maxwell W. Tom Breakdown of academic impact, for papers by Jung‐Il Lee Breakdown of academic impact, for papers by Richard J. Dahl Breakdown of academic impact, for papers by Heyoung L. McBride Breakdown of academic impact, for papers by P.K. Sneed
Rankless by CCL
2026